True – although I must agree with you, Koos has recognized the importance of having the shareholders support while achieving every step or milestone he and the BMSN team have set up on their timeline. Coincidentally, the PR is not required; however, I think Koos would do the diligence to inform the BMSN shareholders of the FDA results.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.